Quick Answer
SELLAS Life Sciences Group, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2023.
SELLAS Life Sciences Group, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $0.00 | -100.0% |
| 2022 | $1.00M | -86.8% |
| 2021 | $7.60M | +300.0% |
| 2020 | $1.90M | — |
| 2019 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
| March 31, 2023 | $0.00 | -100.0% | — |
| September 30, 2022 | $0.00 | — | — |
| June 30, 2022 | $0.00 | -100.0% | -100.0% |
| March 31, 2022 | $1.00M | -82.5% | — |
| September 30, 2021 | $0.00 | — | -100.0% |
| June 30, 2021 | $1.90M | — | -66.7% |
- SELLAS Life Sciences Group, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from SELLAS Life Sciences Group, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 28, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: